What is COSCIENS Biopharma Inc (CSCI)?

Análisis de la acción COSCIENS Biopharma Inc (CSCI)

$2.720

-0.318 (-11.69%)Al cierre

Loading chart…

High: 2.975
Open: 2.960
VWAP: 2.73
Vol: 58.61K
Mkt Cap: —
Low: 2.500
Amount: 160.11K
EV/EBITDA, TTM: 0.00

COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

www.cosciensbio.com

Métricas de valoración

The current forward P/E ratio for COSCIENS Biopharma Inc (CSCI) is 0.16, compared to its 5-year average forward P/E of -1.33.

Forward P/E

Fair

5Y Average P/E

-1.33

Current P/E

0.16

Sobrevalorada

0.36

Infravalorada

-3.02

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.03

Current EV/EBITDA

0.00

Sobrevalorada

0.04

Infravalorada

-0.10

Forward P/S

Fair

5Y Average P/S

5.20

Current P/S

0.79

Sobrevalorada

11.36

Infravalorada

-0.96

Cronología de eventos

2025-05-26 (ET)